Vela Diagnostics' Sentosa® SX101 instrument receives Taiwan FDA approval
Singapore (January 5, 2018) – Vela Diagnostics announced today that the Sentosa® SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use. The Sentosa® SX101 instrument is a multi purpose liquid handling platform and can process 21 various sample types. It features open channel capabilities for automated sample extraction, PCR set-up, NGS library preparation, Sanger sequencing cleanup and many more.
The Sentosa® SX101 instrument is validated for the use with Vela’s highly automated and integrated PCR and NGS workflow. As a part of the NGS workflow the Sentosa® SX101 instrument executes sample extraction and NGS library preparation with ease, while reducing technician hands-on time. In the PCR set-up, the Sentosa® SX101 effortlessly carries out sample extraction and proceeds to set up samples for downstream real-time PCR in various output formats (rotor disc or 96-well); in addition, Sentosa® FLEX application that runs on SX101 allows random access: assignment of different assay combination to each sample for maximum flexibility and efficient reagent reuse. Finally, the Sentosa® SX101 instrument helps to prevent false results due to human error thanks to comprehensive system checks before each run, clear sample traceability, continuous audit trail, seamless LIS integration and bi-directional connectivity.
With the approval in Taiwan, Vela Diagnostics is entering the Taiwanese IVD market and plans to continue to expand its approved portfolio in this territory. To learn more about the Sentosa® SX101 instrument visit: http://www.veladx.com/product/ngs-instruments/Sentosa®-sx101.html